Exploring predictors of response: immune biomarkers
Research in the field of immune-biomarkers seeks to characterize immune activity in the tumor microenvironment. The unique patterns of immune-biomarker expression, as well as their interactions, determine the balance of immune activation versus suppression.1,2 These factors are important considerations to ensure an accurate and comprehensive assessment of the clinical relevance of immune-biomarkers.
Bristol-Myers Squibb is leading the exploration of immune-biomarkers in Immuno-Oncology.
Learn more about immune-biomarkers in cancer
1. Gkretsi V, Stylianou A, Papageorgis P, Polydorou C, Stylianopoulos T. Remodeling components of the tumor microenvironment to enhance cancer therapy. Front Oncol. 2015;5:214. doi:10.3389/fonc.2015.00214. 2. Nelson D, Fisher S, Robinson B. The ‘‘Trojan Horse’’ Approach to Tumor Immunotherapy: Targeting the Tumor Microenvironment. J Immunol Res. 2014;2014:789069. doi:10.1155/2014/789069.